| Dendreon’s Provenge Gets FDA Approval - Now What? We have been closely following Dendreon (DNDN) since back in 2003 when they had their first successful Phase 3 results for their immunotherapy treatment for prostate cancer, then known as sipuleucel-T. Provenge, as it is now called, was finally approved by the FDA Thursday. Provenge is a whole new paradigm for treatment: instead of directly attacking the cancer, it "trains" the body's own immune system to do the job. So far, Provenge has only been tested in men with advanced cancer (and weaker immune systems) and the fact that it positively effects survival in that population could be an indication that it may be even more effective when given to earlier-stage patients (with stronger immune systems).Complete Story » seekingalpha.com |
Eight Nations Picked as Health-Aid Labs The Obama administration has picked eight countries to serve as learning labs for a global health strategy aimed in part at reducing maternal and child deaths and combatting disease. online.wsj.com |
Persistent Back Pain? Think Spondylitis. - Video Spondylitis Association of America (SAA) Launches Public Service Announcements to Hasten Arthritis Diagnosis feedproxy.google.com |
Roche Boosts China Presence Roche is increasing its investments in China to accommodate the country's growing health-care needs, its chief executive said. online.wsj.com |
FDA Warns on Mouth-Rinse Marketing The FDA warned Johnson & Johnson, CVS Caremark and Walgreen to stop marketing mouth-rinse products with claims that they reduce plaque above the gum line or promote healthy gums. online.wsj.com |